Conagra Brands vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Chicago packaged frozen food brands (NYSE: CAG) ~$11.9B FY2025 revenue; Birds Eye 40%+ frozen veggie share, Slim Jim #1 convenience meat snack, Pinnacle Foods acquisition 2018 competing with Nestlé and General Mills.
About
Conagra Brands, Inc. is a Chicago, Illinois-based packaged food company — publicly traded on the New York Stock Exchange (NYSE: CAG) as an S&P 500 Consumer Staples component — marketing a portfolio of branded consumer foods and foodservice products including frozen meals (Birds Eye, Healthy Choice, Marie Callender's, Banquet), condiments and sauces (Hunt's, Slim Jim, Duncan Hines, Vlasic), snacks (Angie's BOOM CHICKA POP, Bigs seeds, Orville Redenbacher's), and international brands through approximately 18,000 employees. In fiscal year 2025 (ending May 2025), Conagra reports revenues of approximately $11.9 billion, navigating consumer trade-down behavior (consumers buying fewer premium branded frozen meals and choosing lower-price options or home-cooked meals) and competitive private label penetration in frozen meal categories (Birds Eye, Healthy Choice, and Marie Callender's facing increased competition from Kroger, Walmart, and Costco private label frozen meal options priced 20-30% below branded alternatives). CEO Sean Connolly has executed Conagra's "Conagra Way" transformation: divesting commodity businesses (Lamb Weston potato processing — spun off as independent public company in 2016; private label operations sold) and building the brand portfolio through the 2018 acquisition of Pinnacle Foods ($10.9 billion — adding Birds Eye, Duncan Hines, Vlasic, and Gardein plant-based foods) — concentrating Conagra's capital and marketing investment on premium branded frozen and packaged food categories where Conagra holds #1 or #2 market share positions. Conagra's frozen vegetable leadership (Birds Eye — 40%+ US frozen vegetable market share) and frozen meal portfolio (Healthy Choice café steamers, Marie Callender's pot pies and dinners) position the company in categories that benefit from the "cooking-at-home" preference when dining out costs rise.
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.